Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company was founded in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930
Debt
Debt-to-Equity RatioN/A
Current Ratio19.66
Quick Ratio19.66
Price-To-Earnings
Trailing P/E Ratio-11.73
Forward P/E Ratio-11.55
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.73 per share
Price / Book9.92
Profitability
EPS (Most Recent Fiscal Year)($4.00)
Net Income$-119,490,000.00
Net MarginsN/A
Return on Equity-51.97%
Return on Assets-46.59%
Miscellaneous
Employees185
Outstanding Shares43,950,000
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.12. View Atara Biotherapeutics' Earnings History.
What price target have analysts set for ATRA?
9 analysts have issued 12 month price targets for Atara Biotherapeutics' shares. Their forecasts range from $20.00 to $70.00. On average, they expect Atara Biotherapeutics' share price to reach $43.00 in the next year. View Analyst Ratings for Atara Biotherapeutics.
What are Wall Street analysts saying about Atara Biotherapeutics stock?
Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (6/6/2018)
- 2. Canaccord Genuity analysts commented, "We are updating details of our model and valuation table for ATRA, but our price target remains at $70 and our revenue estimates remain unchanged." (3/13/2018)
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Repligen (RGEN), Editas Medicine (EDIT), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI) and Sangamo Therapeutics (SGMO).
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 47)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 48)
- Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 47)
- Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 52)
- John Craighead, VP of Investor Relations & Corp. Communications
Has Atara Biotherapeutics been receiving favorable news coverage?
Media headlines about ATRA stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a daily sentiment score of 0.18 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.89 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Atara Biotherapeutics' major shareholders?
Atara Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (17.70%), Redmile Group LLC (9.64%), BlackRock Inc. (6.47%), Artal Group S.A. (2.84%), Neuberger Berman Group LLC (2.49%) and Federated Investors Inc. PA (1.08%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.
Which institutional investors are selling Atara Biotherapeutics stock?
ATRA stock was sold by a variety of institutional investors in the last quarter, including Old West Investment Management LLC and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.
Which institutional investors are buying Atara Biotherapeutics stock?
ATRA stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Federated Investors Inc. PA, PointState Capital LP, Artal Group S.A., Northern Trust Corp, UBS Group AG and Pacific Heights Asset Management LLC. View Insider Buying and Selling for Atara Biotherapeutics.
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $46.90.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $1.99 billion. The biotechnology company earns $-119,490,000.00 in net income (profit) each year or ($4.00) on an earnings per share basis. Atara Biotherapeutics employs 185 workers across the globe.
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
